Diurnal ltd., a neurocrine biosciences company, presents phase 3 extension study data for modified-release hydrocortisone in patients with congenital adrenal hyperplasia at endo 2023

San diego , june 15, 2023 /prnewswire/ -- diurnal ltd., a neurocrine biosciences company (nasdaq: nbix), today announced that it will present new post hoc analyses of phase 3 extension study data for modified-release hydrocortisone (approved as efmody® in united kingdom and european union), which is being investigated as a treatment for adults with congenital adrenal hyperplasia (cah), at endo 2023 june 15–18 in chicago.
NBIX Ratings Summary
NBIX Quant Ranking